Compare DexCom, Inc. (DXCM) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? DexCom, Inc. trades at $90.81 (market cap $33.79B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.96. The key difference: DexCom, Inc. is trading nearer its 52-week high, Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | PDBC | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | — |
52-Week High | $89.53 | $18.91 |
52-Week Low | $54.84 | $12.90 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
PDBC trades at $17.94, up 0.62% with strong bullish technical signals from moving averages and a neutral RSI. The ETF has gained institutional interest with recent large purchases by Geneos Wealth Management and Advisortrust Partners. Commodity markets face geopolitical tensions that could drive volatility, while PDBC's structure avoids K-1 tax complexities but carries roll costs. Recent performance shows 37% returns since March 2024, outpacing the S&P 500 by 10 percentage points.
Outlook remains cautiously optimistic given commodity strength and defensive rotation trends, though momentum has recently weakened. Key risks include Middle East tensions affecting oil supplies, interest rate uncertainty, and inherent commodity volatility. The ETF offers diversified commodity exposure without K-1 tax forms, making it attractive for inflation hedging despite structural costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
